{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:42:09Z","timestamp":1763037729695,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the scientific research team training project of guangzhou university of chinese medicine","award":["2019KYTD101"],"award-info":[{"award-number":["2019KYTD101"]}]},{"DOI":"10.13039\/100014717","name":"national outstanding youth science fund project of national natural science foundation of china","doi-asserted-by":"publisher","award":["81904133"],"award-info":[{"award-number":["81904133"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012241","name":"Guangzhou Research Collaborative Innovation Projects","doi-asserted-by":"publisher","award":["2021XK18"],"award-info":[{"award-number":["2021XK18"]}],"id":[{"id":"10.13039\/501100012241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Myasthenia gravis (MG) is an acquired autoimmune disease with high heterogeneity. The disease is chronic, relapsing repeatedly and progressive with acute exacerbation occasionally. Although the treatment of MG has developed, it is still unsatisfactory and has some unexpected side effects. Traditional Chinese medicine (TCM) has shown great potential in MG treatment, including relief of muscle weakness syndrome, improvement of patient\u2019s quality of life, and reduction of side effects of western medicine. The purpose of this study is to evaluate the effectiveness of modified Buzhong Yiqi decoction (MBYD) as an add-on therapy for MG through a small series of N-of-1 trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Single-centre, randomized, double-blind, 3 crossover N-of-1 trials will be conducted to enroll patients with MG diagnosed as spleen-stomach deficiency syndrome or spleen-kidney deficiency syndrome in TCM. Each N-of-1 trial has 3\u2009cycles of two 4-week periods containing the MBYD period and placebo period. The wash-out interval of 1 week is prior to switching each period. Primary outcome: quantitative myasthenia gravis (QMG). Secondary outcomes: the following scales: myasthenia gravis composite (MGC), myasthenia gravis activities of daily living profile (MG-ADL), myasthenia gravis quality of life (MG-QOL); the level of CD4+FoxP3+Treg cells and cytokines (IL-4, IL-17A, INF-\u03b3, TGF-\u03b2) in the peripheral blood; the alterations of the composition of gut microbiota; reduction of the side effects of western medicine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Used by WinBUGS software, we will conduct a hierarchical Bayesian statistical method to analyze the efficacy of MBYD in treating MG in individuals and populations. Some confounding variables such as TCM syndrome type and potential carryover effect of TCM will be introduced into the hierarchical Bayesian statistical method to improve the sensitivity and applicability of the trials, and the use of prior available information within the analysis may improve the sensitivity of the results of a series of N-of-1 trials, from both the individual and population level to study the efficacy of TCM syndrome differentiation. We assumed that this study would reveal that MBYD is effective for MG and provide robust evidence of the efficacy of TCM to treat MG.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Chinese Clinical Trial Register, ID: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=64688\">ChiCTR2000040477<\/jats:ext-link>, registration on 29 November 2020.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06287-9","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T11:03:15Z","timestamp":1651057395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness of modified Buzhong Yiqi decoction in treating myasthenia gravis: study protocol for a series of N-of-1 trials"],"prefix":"10.1186","volume":"23","author":[{"given":"Senhui","family":"Weng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benshu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuotai","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qilong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"issue":"1","key":"6287_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","volume":"14","author":"A Bubuioc","year":"2021","unstructured":"Bubuioc A, Kudebayeva A, Turuspekova S, Lisnic V, Leone M. The epidemiology of myasthenia gravis. J Med Life. 2021;14(1):7\u201316. https:\/\/doi.org\/10.25122\/jml-2020-0145.","journal-title":"J Med Life"},{"issue":"5-6","key":"6287_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3109\/08916930903555943","volume":"43","author":"A Gomez","year":"2010","unstructured":"Gomez A, Van Den Broeck J, Vrolix K, Janssen S, Lemmens M, Van Der Esch E, et al. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity. 2010;43(5-6):353\u201370. https:\/\/doi.org\/10.3109\/08916930903555943.","journal-title":"Autoimmunity."},{"issue":"3","key":"6287_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/cei.12804","volume":"185","author":"A Rodr\u00edguez-Perea","year":"2016","unstructured":"Rodr\u00edguez-Perea A, Arcia E, Rueda C, Velilla P. Phenotypical characterization of regulatory T cells in humans and rodents. Clin Exp Immunol. 2016;185(3):281\u201391. https:\/\/doi.org\/10.1111\/cei.12804.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"6287_CR4","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/cei.13546","volume":"203","author":"A Uzawa","year":"2021","unstructured":"Uzawa A, Kuwabara S, Suzuki S, Imai T, Murai H, Ozawa Y, et al. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol. 2021;203(3):366\u201374. https:\/\/doi.org\/10.1111\/cei.13546.","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"6287_CR5","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. J Clin Med. 2021;10(11):2235.","journal-title":"J Clin Med"},{"key":"6287_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.phrs.2019.02.024","volume":"142","author":"W Feng","year":"2019","unstructured":"Feng W, Ao H, Peng C, Yan D. Gut microbiota, a new frontier to understand traditional Chinese medicines. Pharmacol Res. 2019;142:176\u201391. https:\/\/doi.org\/10.1016\/j.phrs.2019.02.024.","journal-title":"Pharmacol Res"},{"key":"6287_CR7","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.3389\/fmicb.2018.02627","volume":"9","author":"D Qiu","year":"2018","unstructured":"Qiu D, Xia Z, Jiao X, Deng J, Zhang L, Li J. Altered Gut Microbiota in Myasthenia Gravis. Front Microbiol. 2018;9:2627. https:\/\/doi.org\/10.3389\/fmicb.2018.02627.","journal-title":"Front Microbiol"},{"issue":"18","key":"6287_CR8","doi-asserted-by":"publisher","first-page":"1901441","DOI":"10.1002\/advs.201901441","volume":"6","author":"P Zheng","year":"2019","unstructured":"Zheng P, Li Y, Wu J, Zhang H, Huang Y, Tan X, et al. Perturbed Microbial Ecology in Myasthenia Gravis: Evidence from the Gut Microbiome and Fecal Metabolome. Adv Sci (Weinh). 2019;6(18):1901441. https:\/\/doi.org\/10.1002\/advs.201901441.","journal-title":"Adv Sci (Weinh)"},{"key":"6287_CR9","doi-asserted-by":"publisher","first-page":"6512572","DOI":"10.1155\/2017\/6512572","volume":"2017","author":"XQ Yang","year":"2017","unstructured":"Yang XQ, Liu L, Yang WY, Dong HH, Yang YR, Li Y. Efficacy and Safety of the TCM Qi-Supplementing Therapy in Patients with Myasthenia Gravis: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2017;2017:6512572\u201310. https:\/\/doi.org\/10.1155\/2017\/6512572.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"50","key":"6287_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013677","volume":"97","author":"X Jiang","year":"2018","unstructured":"Jiang X, Chen G, Huang J, Xie L, Shen D, Jiang K, et al. Modified Buzhong Yiqi decoction for myasthenia gravis: A systematic review protocol. Medicine. 2018;97(50):e13677. https:\/\/doi.org\/10.1097\/MD.0000000000013677.","journal-title":"Medicine."},{"issue":"51","key":"6287_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023679","volume":"99","author":"S Weng","year":"2020","unstructured":"Weng S, Fan Z, Qiu G, Liu F, Huang L, Li J, et al. Therapeutic efficacy and immunoregulatory effect of Qiangji Jianli Capsule for patients with myasthenia gravis: Study protocol for a series of randomized, controlled N-of-1 trials. Medicine. 2020;99(51):e23679. https:\/\/doi.org\/10.1097\/MD.0000000000023679.","journal-title":"Medicine."},{"issue":"21","key":"6287_CR12","first-page":"3336","volume":"15","author":"L Xinyan","year":"2020","unstructured":"Xinyan L, Lei F. Effects of Buzhong Yiqi Decoction on Treg Lymphocyte, Lymphocyte Subsets and on the Curative Effects of Elderly Patients with Myasthenia Gravis. World Chin Med. 2020;15(21):3336\u20139.","journal-title":"World Chin Med"},{"issue":"11","key":"6287_CR13","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1021\/acs.jcim.5b00449","volume":"55","author":"L Cui","year":"2015","unstructured":"Cui L, Wang Y, Liu Z, Chen H, Wang H, Zhou X, et al. Discovering New Acetylcholinesterase Inhibitors by Mining the Buzhongyiqi Decoction Recipe Data. J Chem Inf Model. 2015;55(11):2455\u201363. https:\/\/doi.org\/10.1021\/acs.jcim.5b00449.","journal-title":"J Chem Inf Model"},{"key":"6287_CR14","first-page":"2432","volume":"34","author":"YY Huang","year":"2014","unstructured":"Huang YY. ntegrated traditional Chinese and Western medicine in the treatment of 18 cases of myasthenia gravis. Henan Trad Chin Med. 2014;34:2432\u20133.","journal-title":"Henan Trad Chin Med"},{"key":"6287_CR15","unstructured":"Zu LH. Effective observation on treating myasthenia gravis with the Buzhong Yiqi decoction plus hormone. Clin J Chin Med. 2015:28\u201376."},{"issue":"10","key":"6287_CR16","first-page":"19044","volume":"8","author":"G Qi","year":"2015","unstructured":"Qi G, Gu S, Liu P, Yang H, Dong H. Effects of combined traditional Chinese medicine with immunosuppressive agents for patients with myasthenia gravis. Int J Clin Exp Med. 2015;8(10):19044\u201350.","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"6287_CR17","doi-asserted-by":"publisher","first-page":"16130","DOI":"10.1038\/ncomms16130","volume":"8","author":"C Chang","year":"2017","unstructured":"Chang C, Lin C, Lu C, Martel J, Ko Y, Ojcius D, et al. Corrigendum: Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nat Commun. 2017;8(1):16130. https:\/\/doi.org\/10.1038\/ncomms16130.","journal-title":"Nat Commun"},{"key":"6287_CR18","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3389\/fmicb.2017.02146","volume":"8","author":"M Lyu","year":"2017","unstructured":"Lyu M, Wang Y, Fan G, Wang X, Xu S, Zhu Y. Balancing Herbal Medicine and Functional Food for Prevention and Treatment of Cardiometabolic Diseases through Modulating Gut Microbiota. Front Microbiol. 2017;8:2146. https:\/\/doi.org\/10.3389\/fmicb.2017.02146.","journal-title":"Front Microbiol"},{"issue":"2","key":"6287_CR19","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1177\/0962280217726801","volume":"28","author":"S Senn","year":"2019","unstructured":"Senn S. Sample size considerations for n-of-1 trials. Stat Methods Med Res. 2019;28(2):372\u201383. https:\/\/doi.org\/10.1177\/0962280217726801.","journal-title":"Stat Methods Med Res"},{"key":"6287_CR20","volume-title":"The Oxford Levels of Evidence 2","author":"OCEBM","year":"2011","unstructured":"OCEBM, Levels of Evidence Working Group. The Oxford Levels of Evidence 2. Oxford: Oxford Centre for Evidence-Based, Medicine; 2011."},{"key":"6287_CR21","doi-asserted-by":"publisher","first-page":"5813767","DOI":"10.1155\/2018\/5813767","volume":"2018","author":"H Huang","year":"2018","unstructured":"Huang H, Yang P, Wang J, Wu Y, Zi S, Tang J, et al. Investigation into the Individualized Treatment of Traditional Chinese Medicine through a Series of N-of-1 Trials. Evid Based Complement Alternat Med. 2018;2018:5813767\u201311. https:\/\/doi.org\/10.1155\/2018\/5813767.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"2","key":"6287_CR22","first-page":"44","volume":"24","author":"J Li","year":"2018","unstructured":"Li J, Wei D, Niu J, Yang M, Ge L, Wang X, et al. Potential Facilitators and Barriers to Awareness of N-of-1 Trials for Physicians in Traditional Chinese Medicine. Altern Ther Health Med. 2018;24(2):44\u20139.","journal-title":"Altern Ther Health Med"},{"issue":"2","key":"6287_CR23","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1007\/s12561-016-9165-9","volume":"9","author":"T Xie","year":"2017","unstructured":"Xie T, Yu Z. N-of-1 Design and Its Applications to Personalized Treatment Studies. Stati Biosci. 2017;9(2):662\u201375. https:\/\/doi.org\/10.1007\/s12561-016-9165-9.","journal-title":"Stati Biosci"},{"key":"6287_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ctim.2019.08.014","volume":"46","author":"J Li","year":"2019","unstructured":"Li J, Hu J, Zhai J, Niu J, Kwong J, Ge L, et al. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM) : Recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180\u20138. https:\/\/doi.org\/10.1016\/j.ctim.2019.08.014.","journal-title":"Complement Ther Med"},{"issue":"jan08 15","key":"6287_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin J, et al. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346(jan08 15):e7586. https:\/\/doi.org\/10.1136\/bmj.e7586.","journal-title":"BMJ."},{"key":"6287_CR26","doi-asserted-by":"publisher","unstructured":"Vohra S, Shamseer L, Sampson M, et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. BMJ. 2015;350:h1738. https:\/\/doi.org\/10.1136\/bmj.h1738.","DOI":"10.1136\/bmj.h1738"},{"issue":"01","key":"6287_CR27","first-page":"1","volume":"28","author":"C Ting","year":"2021","unstructured":"Ting C. The Chinese guidelines for the diagnosis and treatment of myasthenia gravis (2020). Chin J Neuroimmunol Neurol. 2021;28(01):1\u201312.","journal-title":"Chin J Neuroimmunol Neurol"},{"key":"6287_CR28","volume-title":"China Press of Traditional Chinese Medicine","author":"China Association of Chinese Medicine","year":"2020","unstructured":"China Association of Chinese Medicine. The guidelines for clinical diagnosis and treatment of internal medicine of traditional Chinese Medicine [M]. In: China Press of Traditional Chinese Medicine; 2020."},{"issue":"1","key":"6287_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16\u201323.","journal-title":"Neurology."},{"key":"6287_CR30","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.2147\/IDR.S281274","volume":"13","author":"S Gu","year":"2020","unstructured":"Gu S, Gong Y, Zhang J, Chen Y, Wu Z, Xu Q, et al. Effect of the Short-Term Use of Fluoroquinolone and \u03b2-Lactam Antibiotics on Mouse Gut Microbiota. Infect Drug Resistance. 2020;13:4547\u201358. https:\/\/doi.org\/10.2147\/IDR.S281274.","journal-title":"Infect Drug Resistance"},{"issue":"1 MYASTHENIA GR","key":"6287_CR31","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"R Barohn","year":"1998","unstructured":"Barohn R, McIntire D, Herbelin L, Wolfe G, Nations S, Bryan W. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841(1 MYASTHENIA GR):769\u201372. https:\/\/doi.org\/10.1111\/j.1749-6632.1998.tb11015.x.","journal-title":"Ann N Y Acad Sci"},{"key":"6287_CR32","unstructured":"Wenfeng Z.\"Diagnosis standards for common syndromes in traditional Chinese medicine\".\u00a0J Hunan Univercity Chin Med. 2008(05):3\u20138+20. [in Chinese]"},{"issue":"12","key":"6287_CR33","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.jclinepi.2010.04.020","volume":"63","author":"D Zucker","year":"2010","unstructured":"Zucker D, Ruthazer R, Schmid C. Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. J Clin Epidemiol. 2010;63(12):1312\u201323. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.020.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"6287_CR34","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0895-4356(96)00429-5","volume":"50","author":"D Zucker","year":"1997","unstructured":"Zucker D, Schmid C, McIntosh M, D'Agostino R, Selker H, Lau J. Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. J Clin Epidemiol. 1997;50(4):401\u201310. https:\/\/doi.org\/10.1016\/S0895-4356(96)00429-5.","journal-title":"J Clin Epidemiol"},{"key":"6287_CR35","unstructured":"Edwards LK. Applied Analysis of Variance in Behavioral Science. M. Dekker. 1993:297\u2013344."},{"key":"6287_CR36","doi-asserted-by":"publisher","unstructured":"Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. Chichester, Hoboken: Wiley; 2004. https:\/\/doi.org\/10.1002\/0470092602.","DOI":"10.1002\/0470092602"},{"issue":"10","key":"6287_CR37","first-page":"2069","volume":"33","author":"D Zucker","year":"2006","unstructured":"Zucker D, Ruthazer R, Schmid C, Feuer J, Fischer P, Kieval R, et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. J Rheumatol. 2006;33(10):2069\u201377.","journal-title":"J Rheumatol"},{"issue":"1","key":"6287_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3233\/NRE-161386","volume":"40","author":"J Nikles","year":"2017","unstructured":"Nikles J, Mitchell G, McKinlay L, Waugh M, Epps A, Carmont S, et al. A series of n-of-1 trials of stimulants in brain injured children. NeuroRehabilitation. 2017;40(1):11\u201321. https:\/\/doi.org\/10.3233\/NRE-161386.","journal-title":"NeuroRehabilitation."},{"key":"6287_CR39","doi-asserted-by":"publisher","first-page":"9976770","DOI":"10.1155\/2021\/9976770","volume":"2021","author":"L Lu","year":"2021","unstructured":"Lu L, An J, Chen H, Yang P, Xu M, Wu Y, et al. A Series of N-of-1 Trials for Traditional Chinese Medicine Using a Bayesian Method: Study Rationale and Protocol. Evid Based Complement Alternat Med. 2021;2021:9976770\u20138. https:\/\/doi.org\/10.1155\/2021\/9976770.","journal-title":"Evid Based Complement Alternat Med"},{"key":"6287_CR40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jclinepi.2015.09.020","volume":"76","author":"G Guyatt","year":"2016","unstructured":"Guyatt G. N of 1 randomized trials: a commentary. J Clin Epidemiol. 2016;76:4\u20135.","journal-title":"J Clin Epidemiol"},{"key":"6287_CR41","doi-asserted-by":"publisher","unstructured":"Li J, Gao W, Punja S, Ma B, Vohra S, Duan N, et al. Reporting quality of N-of-1 trials published between 1985 and 2013: a systematic review. J Clin Epidemiol. 2016;76:57\u201364. https:\/\/doi.org\/10.1016\/j.jclinepi.2015.11.016.","DOI":"10.1016\/j.jclinepi.2015.11.016"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06287-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06287-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06287-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T11:09:47Z","timestamp":1651057787000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06287-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6287"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06287-9","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"1 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients we recruited will provide written informed consent before participation. Ethical approval was acquired from the Ethics Committee of The First Affiliated Hospital of GZUCM, No. ZYYECK[2019]119. We will bear the cost of granules and relevant examinations during the study. Data usage will obey the ordinances of the hospital\u2019s data oversight committee. De-identify results will be announced in peer-reviewed journals and be presented in academic meetings and scientific conferences. The results will also be informed to the participants at the end of the trials.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors gave their consent to publish the paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SW and JL contributed equally and are co-first authors. The authors declare that they have no competing interests","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"365"}}